Rxsight, Inc. Stock Price, News & Analysis

RxSight (NASDAQ: RXST) announced preliminary Q1 2025 revenue of $37.9 million, showing 28% year-over-year growth but a 6% decrease from Q4 2024. The company reported selling 27,579 Light Adjustable Lenses, a 36% increase from Q1 2024, and 73 Light Delivery Devices, expanding the installed base to 1,044 LDDs (43% growth year-over-year).

Due to headwinds in the premium IOL market and broader economy, RxSight revised its 2025 guidance downward. The new full-year revenue guidance is $160.0-175.0 million (down from $185.0-197.0 million), representing 14-25% growth. Operating expenses are now projected at $150.0-160.0 million, reduced from $165.0-170.0 million, including non-cash stock-based compensation of $27.0-30.0 million.

RxSight (NASDAQ: RXST), an ophthalmic medical device company focused on post-cataract surgery customized vision solutions, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's management will engage in a fireside chat scheduled for April 8, 2025, at 9:45 AM PT / 12:45 PM ET. Interested parties can access both the live presentation and archived recording through RxSight's investor relations website at https://investors.rxsight.com/.

RxSight (RXST) reported strong Q4 and full-year 2024 financial results. Q4 revenue reached $40.2 million, up 41% year-over-year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 Light Delivery Devices (LDD™s). The LDD installed base expanded to 971 units.

Full-year 2024 revenue grew 57% to $139.9 million, with 98,055 LALs and 305 LDDs sold. Gross profit margin improved to 71.6% in Q4 2024, up from 61.8% in Q4 2023. The company reported a reduced Q4 net loss of $(5.9) million compared to $(9.2) million in Q4 2023.

For 2025, RxSight reaffirmed guidance projecting revenue of $185.0-197.0 million (32-41% growth), gross margin of 71-73%, and operating expenses of $165.0-170.0 million.

RxSight (RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has announced it will release its fourth quarter 2024 financial results on February 25, 2025, after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone at (800) 715-9871 or (646) 307-1963 using conference code 7159871, or listen to the webcast through the company's investor relations website. A recording will be available after the call.

RxSight (NASDAQ: RXST) reported preliminary Q4 2024 revenue of $40.2 million, up 41% year-over-year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 Light Delivery Devices (LDD™s). The company's installed base reached 971 LDDs, a 46% increase from Q4 2023.

Full-year 2024 revenue is expected at $139.9 million, representing 57% growth, with 98,055 LALs sold and 305 LDDs installed. The company now serves approximately 15% of North American cataract surgeons, with LAL procedures representing over 10% of the region's premium IOL market.

For 2025, RxSight projects revenue between $185.0-197.0 million (32-41% growth), with gross profit margins of 71-73% and operating expenses of $165.0-170.0 million. Cash position as of December 31, 2024, was $237.2 million.

RxSight (NASDAQ: RXST), an ophthalmic medical device company focused on providing customized vision solutions for post-cataract surgery patients, has announced its participation in the upcoming J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at investors.rxsight.com.

RxSight reported strong Q3 2024 financial results with revenue of $35.3 million, up 59% year-over-year. The company sold 24,554 Light Adjustable Lenses (LAL™/LAL+™), an 80% increase, and 78 Light Delivery Devices (LDD™s), an 18% increase from Q3 2023. The installed base grew to 888 LDDs, up 51% year-over-year. Gross profit reached $25.2 million with a 71.4% margin. Despite operating expenses of $34.4 million, net loss improved to $(6.3) million. The company raised its 2024 full-year revenue guidance to $140 million, with improved gross margin guidance of 70-71% and lower operating expenses.

RxSight announced it will release its Q3 2024 financial results on November 7, 2024, after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Interested parties can join via phone at (888) 596-4144 or (646) 968-2525 using conference code 7406253. A live webcast will be available in listen-only mode through the investor relations website, with a recording accessible afterward.

RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, has announced its participation in two upcoming healthcare conferences in September 2024. The company will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 at 9:15 a.m. ET in New York City, and the Wells Fargo 2024 Healthcare Conference on September 5 at 3:45 p.m. ET in Boston.

RxSight specializes in providing high-quality customized vision to patients following cataract surgery. Both conference appearances will feature fireside chats with company representatives. Interested parties can access live and archived webcasts of these events through the company's investor relations website at https://investors.rxsight.com/.